Jianfeng Pharmaceutical passed the national high-tech enterprise identification for the fourth time.
Release time:
2020-08-14
Jianfeng Pharmaceutical passed the national high-tech enterprise accreditation
for the fourth time. Before , the Office of the National High-tech Enterprise Accreditation Management Leading Group announced the list of the first batch of high-tech enterprises in Zhejiang Province 2017 , among which Jianfeng Pharmaceutical was listed, and obtained the "High-tech Enterprise Certificate" jointly issued by the Department of Science and Technology of Zhejiang Province, the Department of Finance of Zhejiang Province, the State Taxation Bureau of Zhejiang Province, and the Local Taxation Bureau of Zhejiang Province ". This is also the fourth consecutive time that Jianfeng Pharmaceutical has passed the national high-tech enterprise certification since 2008 .
High-tech enterprise refers to the continuous research and development and the transformation of technological achievements in the high-tech field supported by the state, forming the core independent intellectual property rights of the enterprise, and carrying out business activities on this basis. Enterprises registered in China (excluding Hong Kong, Macao and Taiwan) for more than one year. The selection of high-tech enterprises is based on the core independent intellectual property rights, products or services belonging to the scope of high-tech fields, the proportion of enterprise scientific and technological talents, research and development costs, enterprise innovation ability, scientific and technological achievements transformation ability, growth indicators and other indicators for comprehensive scoring. The identification criteria are very strict. 2016 6 , the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation revised and issued the 2016 edition of the "Guidelines for the Management of High-tech Enterprise Accreditation", which made substantial changes to the accreditation conditions and other contents. In particular, the accreditation standards for the management of R & D and innovation of enterprises have been raised, and the "threshold" for the accreditation of high-tech enterprises has been greatly raised. To this end, Jianfeng Pharmaceutical has prepared corresponding personnel, materials and systems in advance. According to the requirements of the new regulations, it has collected effective and accurate materials, extracted and written application materials, and laid a good foundation for one-time identification.
High-tech enterprise is a special qualification certification established by the state to support and encourage the development of high-tech enterprises, adjust the industrial structure and enhance the national economic competitiveness. It is currently the only national-level enterprise qualification certification. It occupies a very important strategic position in my country's economic development. It is recognized that enterprises generally have high growth and high economic benefits, which is an indispensable hard signboard for enterprises relying on science and technology. As a high-tech enterprise, it can enjoy certain preferential policies in tax reduction and exemption, special fund declaration, bidding, government procurement, etc. According to this confirmation, Jianfeng Pharmaceutical will enjoy the preferential income tax policy for high-tech enterprises within three years from 2017 (2017 1 1 to 2019 12 31 ), I .e. pay the enterprise income tax at the rate of 15% . (Zhu Ningyan)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page